Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRISBANE, CALIF., MAY 08, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON MAY 4, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 40,250 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 20,125 SHARES OF CLASS A COMMON STOCK TO TEN (10) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

U.S. FOOD AND DRUG ADMINISTRATION (FDA) GRANTED PRIORITY REVIEW TO BIOLOGICS LICENSE APPLICATION (BLA) FOR THE ACCELERATED APPROVAL OF ATACICEPT IN ADULT PATIENTS WITH IGA NEPHROPATHY (IGAN) WITH A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE OF JULY 7, 2026 ON TRACK FOR U.S. COMMERCIAL LAUNCH OF ATACICEPT IN MID-2026, PENDING REGULATORY APPROVAL STRONG BALANCE SHEET EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS BEYOND POTENTIAL ATACICEPT APPROVAL AND U.S. COMMERCIAL LAUNCH BRISBANE, CALIF., MAY 07, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY REPORTED ITS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

VERA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

BRISBANE, CALIF., MAY 04, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PRESENT AT THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE, WHICH IS TAKING PLACE IN LAS VEGAS, NV FROM MAY 12-14, 2026.

VERA THERAPEUTICS TO PARTICIPATE IN THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE

BRISBANE, CALIF., APRIL 10, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON APRIL 8, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 258,200 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 131,925 SHARES OF CLASS A COMMON STOCK TO EIGHTY-NINE (89) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

BRISBANE, CALIF., MARCH 27, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON MARCH 23, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 56,850 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 42,403 SHARES OF CLASS A COMMON STOCK TO JANE WRIGHT-MITCHELL, VERA'S NEW CHIEF LEGAL OFFICER UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

BRISBANE, CALIF., MARCH 25, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF JANE WRIGHT-MITCHELL, PHARM.D.

VERA THERAPEUTICS APPOINTS JANE WRIGHT-MITCHELL AS CHIEF LEGAL OFFICER

BRISBANE, CALIF., MARCH 06, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON MARCH 3, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 46,000 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 25,875 SHARES OF CLASS A COMMON STOCK TO SIX (6) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

BRISBANE, CALIF., MARCH 05, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF CHRISTOPHER HITE, AN ACCOMPLISHED EXECUTIVE WITH DECADES OF CORPORATE AND FINANCIAL STRATEGY LEADERSHIP EXPERIENCE IN THE BIOPHARMACEUTICAL SECTOR, TO VERA THERAPEUTICS' BOARD OF DIRECTORS.

VERA THERAPEUTICS APPOINTS CHRISTOPHER HITE TO BOARD OF DIRECTORS

POSITIVE PHASE 3 DATA FROM ORIGIN 3 STUDY OF ATACICEPT IN IGA NEPHROPATHY (IGAN) PRESENTED AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE U.S. FOOD AND DRUG ADMINISTRATION (FDA) GRANTED PRIORITY REVIEW TO BIOLOGICS LICENSE APPLICATION (BLA) FOR ATACICEPT WITH PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE OF JULY 7, 2026; POTENTIAL COMMERCIAL LAUNCH OF ATACICEPT EXPECTED IN MID-2026 STRONG BALANCE SHEET BOLSTERED BY EQUITY AND DEBT FINANCINGS IN 2025 EXPECTED TO BE SUFFICIENT TO FUND COMPANY BEYOND ATACICEPT APPROVAL AND U.S. COMMERCIAL LAUNCH BRISBANE, CALIF., FEB. 26, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY REPORTED ITS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025.

VERA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FULL YEAR 2025 FINANCIAL RESULTS

BRISBANE, CALIF., FEB. 24, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN ONE-ON-ONE MEETINGS AT UPCOMING INVESTOR CONFERENCES.

Vera Therapeutics, Inc.

VERA

Price

Financial Reports

No items found.

Press Releases

Vera Therapeutics, Inc.

VERA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VERA